Quote:
Originally Posted by zanpar321
Thanks. I see they have both passed phase I/safety studies are are hoping to start phase 2 soon.
|
Yes, safety studies were fine, well tolerated, at least short term. They also had very good biomarker results. Prothena showed mean free serum A-Syn reductions up to 96%. Of course, what we don't know at this point, is if reduced free serum levels will actually slow or halt the neuro degenerative effects of misfolded, aggregated, a-Syn. We also don't know if there will be any negative impact from removing normal a-Syn from the body. Remember, this protein is needed for normal neuron functions and is involved as a presynaptic neural transmitter.